These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 33620275)

  • 21. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
    Weir MR; Bakris GL; Bushinsky DA; Mayo MR; Garza D; Stasiv Y; Wittes J; Christ-Schmidt H; Berman L; Pitt B;
    N Engl J Med; 2015 Jan; 372(3):211-21. PubMed ID: 25415805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacology of hyperkalemia].
    Rosano GMC
    G Ital Cardiol (Rome); 2021 Dec; 22(12 Suppl 1):e8-e12. PubMed ID: 34935774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of sodium zirconium cyclosilicate for hyperkalemia among patients with chronic kidney disease or heart failure in Kuwait.
    Elsisi GH; Mahmoud MMI; Al-Humood K; Al-Yousef A
    J Med Econ; 2024; 27(1):253-265. PubMed ID: 38318718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemia.
    Pitt B; Garza D
    Expert Opin Drug Saf; 2018 May; 17(5):525-535. PubMed ID: 29667438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sodium zirconium cyclosilicate: a new potassium binder for the treatment of hyperkalemia.
    Cases A; Gorriz JL
    Drugs Today (Barc); 2018 Oct; 54(10):601-613. PubMed ID: 30398481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Revisiting RAAS blockade in CKD with newer potassium-binding drugs.
    Georgianos PI; Agarwal R
    Kidney Int; 2018 Feb; 93(2):325-334. PubMed ID: 29276100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyperkalemia in heart failure.
    Sidhu K; Sanjanwala R; Zieroth S
    Curr Opin Cardiol; 2020 Mar; 35(2):150-155. PubMed ID: 31833959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperkalemia in heart failure: Foe or friend?
    Rakisheva A; Marketou M; Klimenko A; Troyanova-Shchutskaia T; Vardas P
    Clin Cardiol; 2020 Jul; 43(7):666-675. PubMed ID: 32445223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New drugs for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors -- hype or hope?
    Tamargo J; Caballero R; Delpón E
    Discov Med; 2014 Nov; 18(100):249-54. PubMed ID: 25425465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of potassium binders in the treatment of patients with chronic kidney disease and hyperkalemia.
    Dong L; Xu W; Deng Y; Tan J; Qin W
    Eur J Pharmacol; 2022 Sep; 931():175174. PubMed ID: 35964658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
    Weir MR; Bushinsky DA; Benton WW; Woods SD; Mayo MR; Arthur SP; Pitt B; Bakris GL
    Am J Med; 2018 May; 131(5):555-564.e3. PubMed ID: 29180023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders.
    Sarwar CMS; Bhagat AA; Anker SD; Butler J
    Handb Exp Pharmacol; 2017; 243():537-560. PubMed ID: 28382468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New drugs to prevent and treat hyperkalemia.
    Lepage L; Desforges K; Lafrance JP
    Curr Opin Nephrol Hypertens; 2016 Nov; 25(6):524-528. PubMed ID: 27584929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of Chronic Hyperkalemia in Patients With Chronic Kidney Disease: An Old Problem With News Options.
    Morales E; Cravedi P; Manrique J
    Front Med (Lausanne); 2021; 8():653634. PubMed ID: 34150795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges in Treating Cardiovascular Disease: Restricting Sodium and Managing Hyperkalemia.
    Clegg DJ; Cody M; Palmer BF
    Mayo Clin Proc; 2017 Aug; 92(8):1248-1260. PubMed ID: 28778258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.
    Spinowitz BS; Fishbane S; Pergola PE; Roger SD; Lerma EV; Butler J; von Haehling S; Adler SH; Zhao J; Singh B; Lavin PT; McCullough PA; Kosiborod M; Packham DK;
    Clin J Am Soc Nephrol; 2019 Jun; 14(6):798-809. PubMed ID: 31110051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperkalemia in patients with chronic renal failure.
    Seliger SL
    Nephrol Dial Transplant; 2019 Dec; 34(Suppl 3):iii12-iii18. PubMed ID: 31800076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [New potassium binders effective: treatment of hyperkalaemia secondary to RAAS inhibitors].
    Hoorn EJ
    Ned Tijdschr Geneeskd; 2015; 159():A8801. PubMed ID: 25761299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potassium binding for conservative and preservative management of chronic kidney disease.
    Clegg DJ; Palmer BF
    Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):29-38. PubMed ID: 31714287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia.
    Athyros VG; Sachinidis AG; Zografou I; Simoulidou E; Piperidou A; Stavropoulos N; Karagiannis A
    Curr Pharm Des; 2018; 24(46):5542-5547. PubMed ID: 30848186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.